Sex: F
Vaccine: COVID19
Symptoms: Magnetic resonance imaging heart, Myocarditis, Physical examination, Troponin I
Clinical narrative: Myocarditis; This is a literature report.  A 63-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "rheumatoid arthritis" (unspecified if ongoing); "coronavirus", start date: Mar2020 (unspecified if ongoing); "mixed connective tissue disease" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: MYOCARDITIS (hospitalization, medically significant), 11 hrs after the suspect product(s) administration, outcome "recovered". The event "myocarditis" required emergency room visit. The patient underwent the following laboratory tests and procedures: Computerised tomogram: showed normal coronary arteries,, notes: normal left ventricular function, without regional wall motion abnormalities and normal pericardium; Echocardiogram: shows normal function and no pericardial disease, notes: The long parasternal view; demonstrates normal wall motion and no structural, notes: heart disease. The four-chamber view; revealed neither abnormalities nor, notes: pericardial disease; Electrocardiogram: shows sinus rhythm with no, notes: additional findings and was interpreted as normal; normal without ST changes; remained unchanged; extracellular volume: elevated, notes: in the septum; Magnetic resonance imaging: were compatible with myocarditis; demonstrates late gadolinium, notes: enhancement in the basal inferoseptal and anterolateral wall; shows resolution of edema and scarred fibrosis.; Late gadolinium enhancement short axis imaging, notes: mid-portion shows no delayed enhancement or fibrosis.The four-chamber view demonstrates T1-weighted imaging with no hypertense areas and T2-weighted image shows no residual edema; Magnetic resonance imaging heart: showed abnormal T1 and T2 sequences, notes: an elevated extracellular volume (ECV) in the septum, mid-myocardial late gadolinium enhancement in the basal anteroseptal, inferoseptal, and inferolateral wall segments suggesting focal myocardial edema and fibrosis, performed 11 days post-vaccination; follow-up cardiac MRI, notes: showed resolution of myocarditis findings; physical examination: unremarkable without the findings of, notes: pericardial rub or heart murmur; Troponin I (normal high range 0.03): 0.02 ng/ml, notes: normal; 1.60 ng/ml, notes: risen; Troponin I: rise, notes: during the second day post vaccination; progressive decline and eventual  normalization, notes: on day 12; there were not any detectable levels of the, notes: troponin enzyme. This troponin curve is consistent with myocarditis. After day 12. Therapeutic measures were taken as a result of myocarditis.  Clinical course: A 63-year-old woman with a past medical history of rheumatoid arthritis and mixed connective tissue disease presented to the emergency room (ER) with new onset chest pain 11 h following a third dose of the Pfizer BioNTech coronavirus disease 2019 (COVID-19) vaccination. Her physical examination was unremarkable without the findings of pericardial rub or heart murmur. The patient denied current use of immunosuppressive agents secondary to her autoimmune history at the time of COVID-19 vaccination-induced myocarditis. Of note, the patient was infected with the novel coronavirus in March 2020, with a mild presentation, and was treated with conservative measures and symptom management. Differential diagnoses included myocardial infarction (MI), acute coronary syndrome (ACS), and myocarditis. Initial diagnostic work revealed a normal electrocardiogram (ECG) without ST changes and a normal cardiac troponin I value of 0.02 ng/mL (upper reference limit (URL) < 0.03 ng/mL). The following day, she re-presented with persistent chest pain and her cardiac troponin I had risen to 1.60 ng/mL. A second ECG was taken and remained unchanged. Cardiac computed tomography (CT) showed normal coronary arteries, normal left ventricular function, without regional wall motion abnormalities and normal pericardium. A transthoracic echocardiogram revealed neither abnormalities nor pericardial disease. Serial cardiac troponin measurements were subsequently performed to evaluate the trajectory of her time-concentration curve. Cardiac MRI was performed 11 days post-vaccination and showed abnormal T1 and T2 sequences, an elevated extracellular volume (ECV) in the septum, mid-myocardial late gadolinium enhancement in the basal anteroseptal, inferoseptal, and inferolateral wall segments suggesting focal myocardial edema and fibrosis. This pattern was interpreted to be most consistent with myocarditis. Troponin I time-concentration curve is displayed, demonstrating a rise in troponin I levels during the second day postvaccination followed by a progressive decline and eventual normalization of troponin levels on day 12. After day 12, there were not any detectable levels of the troponin enzyme. This troponin curve is consistent with myocarditis. ECG shows sinus rhythm with no additional findings and was interpreted as normal. The long parasternal view of the echocardiogram shows normal function and no pericardial disease. The four-chamber view of the echocardiogram demonstrates normal wall motion and no structural heart disease. The patient's initial cardiac MRI on the bottom left T1 mapping, and in this case, its value for the septum was elevated, native T2 mapping was elevated which was compatible with edema, on delayed gadolinium enhancement imaging. This is shown with mid-myocardial late gadolinium enhancement in the basal anteroseptal, inferoseptal and inferolateral walls, and T2-weighted image with edema, and all MRI findings were compatible with myocarditis. The patient's 9-month follow-up cardiac MRI demonstrates late gadolinium enhancement in the basal inferoseptal and anterolateral wall (arrows show regions of interest). The MRI shows resolution of edema and scarred fibrosis. Late gadolinium enhancement short axis imaging mid-portion shows no delayed enhancement or fibrosis. The four-chamber view demonstrates T1-weighted imaging with no hypertense areas and T2-weighted image shows no residual edema. The patient was prescribed a 2-month course of colchicine 0.6 mg twice daily starting 8 days status post the third dose of the vaccination. Additionally, a short course of methyl prednisone was initiated 26 days after the third dose of the vaccination for a 6-day treatment with marked reduction in her chest pain syndrome. No non-steroidal anti-inflammatory drugs (NSAIDs) were given for treatment. Nine months later, follow-up cardiac MRI showed resolution of findings suggestive of myocarditis and there was persistent late gadolinium enhancement in the basal inferoseptal and anterolateral wall. She experienced intermittent, self-resolving episodes of pleuritic chest pain over the subsequent 6 months. No myocardial injury was documented after the myocarditis episode and follow-up cardiac MRI showed resolution of myocarditis findings. Myocarditis was an infrequent cardiovascular condition that can arise secondary to COVID-19 vaccination. The incidence of myocarditis from the COVID-19 vaccination has been estimated to be 0.00213% (2.13 per 100,000 persons). The highest incidence of myocarditis appears to be in young men with a rate of 0.01069%. The ages of the patients in the report ranged from 16 to 29 and each had received at least one dose of an mRNA vaccine. The pathophysiology of vaccine-induced myocarditis has been hypothesized to hinge on molecular mimicry. Molecular mimicry occurs when the immune-inducing antigen from the vaccine shares structural similarities with binding epitopes found in the myocardium. As a result, lymphocytes in the myocardium activate, creating inflammation and myocyte injury. In a study of 15 patients, aged 17 - 52 with putative myocarditis, 13 had elevated troponin I levels after receiving a COVID-19 vaccine. The use of the Pfizer BioNTech COVID-19 vaccine was associated with 60% of the cases, 33% arose after Moderna vaccination, and 7% occurred after Johnson & Johnson vaccine. In a separate study, 15 children, aged 12 - 18, were hospitalized at the Hospital with myocarditis after receiving the mRNA COVID-19 vaccine. Each patient had experienced chest pain for 1 - 9 days after receiving the vaccine. The 15 patients had elevated troponin levels with a median value of 0.25 ng/mL and a range from 0.08 to 3.15 ng/mL. After discharge, all patients exhibited troponin levels that were decreased yet still elevated above baseline. In the short term, cases of myocarditis from the vaccine seem to be minor. However, further research is needed to understand and evaluate the long-term effects of COVID-19 vaccine-associated cases of myocarditis. In a study of 809 patients below the age of 30 who were diagnosed with myocarditis after receiving an mRNA vaccine, 97.9% had elevated troponin I levels. These results reflect the critical diagnostic role of cardiac troponin for this diagnosis. According to the Centers for Diseases Control and Prevention (CDC), out of the 296 million doses of Pfizer BioNTech and Moderna COVID-19 vaccination, there have been 1,226 cases of myocarditis, yielding a rate of 4.1 incidents per million doses. Most of these studies do not indicate whether myocarditis occurred after a first, second, or third dose. In one study, seven male adolescents aged between 14- and 19-years experienced myocarditis 4 days after receiving the Pfizer BioNTech vaccine. Three of the seven patients exhibited elevated troponin levels ranging from 2.59 to 22.1 ng/mL. The most common treatment reported for COVID-19 vaccine-related myocarditis is the use of NSAIDs (87%), followed by either intravenous immunoglobulin or glucocorticoid, each used in 12% of cases. In our case, a 63-year-old woman presented with chest discomfort 11 h following a third dose of the Pfizer BioNTech COVID-19 vaccination. The patient's troponin I levels were then measured serially. As shown by the cardiac troponin I time-concentration curve, the first day after her vaccination, her cardiac troponin I level was normal (0.02 ng/mL). The following day, it rose to 1.60 ng/mL and then slowly declined, showing a typical curve of troponin in myocarditis. The decline in her cardiac troponin I levels slowly decreased over the following week. Thereafter, she presented with intermittent chest pain and her symptoms were not correlated to troponin measurements, suggesting a non-cardiac etiology for her chest pain. We are reporting a cardiac troponin time-concentration curve after COVID-19 vaccination, suggesting that troponin changes track well with the initial injury. Notable ECG changes were not found in this case. Colchicine was used for treatment in our case, this drug has several mechanisms of action, it binds to tubulin affecting mitosis, leucocyte movement, exocytosis and phagocytosis, it inhibits the expression of selectins leading to a decreased adherence of leucocytes to the inflamed endothelium, and it inhibits NLRP3 inflammasome. Colchicine has been used as part of SARS-CoV-2 myocardial injury treatment and COVID-19 vaccine-related myocarditis, being a common treatment among the cases reported. Another retrospective study showed that in patients with COVID-19 vaccine myocarditis, 48% were treated with colchicine, 35% with aspirin, 20% with ibuprofen, and 5% with steroids. The treatment with colchicine is one of the treatments available among various options for myocarditis.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal relationship between the event myocarditis and suspect drug BNT162B2 cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.